Published in Nucleic Acids Res on August 08, 2013
Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Epigenetics (2014) 0.86
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward? Crit Rev Oncog (2015) 0.85
NaviCell Web Service for network-based data visualization. Nucleic Acids Res (2015) 0.82
Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes. Int J Mol Sci (2015) 0.82
The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations. PLoS One (2016) 0.79
ETS transcription factors in embryonic vascular development. Angiogenesis (2016) 0.79
The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. Front Oncol (2015) 0.76
ROMA: Representation and Quantification of Module Activity from Target Expression Data. Front Genet (2016) 0.75
Structure-function based molecular relationships in Ewing's sarcoma. Biomed Res Int (2015) 0.75
Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res (2003) 103.76
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
The ENCODE (ENCyclopedia Of DNA Elements) Project. Science (2004) 38.24
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A (2000) 18.42
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature (2000) 8.35
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol (2005) 5.68
p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A (2009) 5.05
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J (2010) 4.78
NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol (2001) 4.55
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res (2005) 3.33
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
Mesenchymal stem cell features of Ewing tumors. Cancer Cell (2007) 3.04
FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem (2002) 2.90
Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol (2007) 2.66
TRANSPATH: an information resource for storing and visualizing signaling pathways and their pathological aberrations. Nucleic Acids Res (2006) 2.55
IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science (1998) 2.46
N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol (2004) 2.11
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res (2006) 1.80
Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol (2010) 1.80
Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics (2010) 1.77
Genetics. Getting closer to the whole picture. Science (2007) 1.73
A molecular function map of Ewing's sarcoma. PLoS One (2009) 1.69
A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle (2007) 1.66
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol (2005) 1.66
Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res (1996) 1.65
BiNoM: a Cytoscape plugin for manipulating and analyzing biological networks. Bioinformatics (2007) 1.65
The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One (2009) 1.63
Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol (2009) 1.63
A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol (2008) 1.61
EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest (1997) 1.61
Inferring qualitative relations in genetic networks and metabolic pathways. Bioinformatics (2000) 1.60
The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene (2007) 1.53
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene (2001) 1.53
Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium. Mol Endocrinol (2005) 1.51
Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci U S A (2008) 1.43
Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res (2005) 1.39
EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res (2008) 1.38
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem (2003) 1.34
Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. Apoptosis (2003) 1.32
De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-Seq data analysis. Nucleic Acids Res (2010) 1.30
Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene (2003) 1.27
Prognostic impact of P53 status in Ewing sarcoma. Cancer (2000) 1.27
IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation. EMBO J (2002) 1.26
Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res (2004) 1.25
Looking beyond the details: a rise in system-oriented approaches in genetics and molecular biology. Curr Genet (2002) 1.23
Visual setup of logical models of signaling and regulatory networks with ProMoT. BMC Bioinformatics (2006) 1.22
The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination. Biochem Biophys Res Commun (2006) 1.14
EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo. Cancer Res (2010) 1.08
Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol (2010) 1.06
E2F-1 regulates expression of FOXO1 and FOXO3a. Biochim Biophys Acta (2007) 1.06
Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res (2010) 1.05
STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res (2011) 1.02
Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer (2004) 1.01
The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. Carcinogenesis (2009) 0.97
MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene (2013) 0.97
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res (2010) 0.96
The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res (2006) 0.95
WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene (2012) 0.95
Qualitative analysis of gene networks. Pac Symp Biocomput (1998) 0.95
Induction of p21Waf1/Cip1 by TNFalpha requires NF-kappaB activity and antagonizes apoptosis in Ewing tumor cells. Oncogene (2000) 0.93
Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth. Cancer Res (2012) 0.92
Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol (2010) 0.90
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet (1999) 0.84
FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells. Biochem Biophys Res Commun (2010) 0.82
Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells. Int J Cancer (2005) 0.82
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Spatial partitioning of the regulatory landscape of the X-inactivation centre. Nature (2012) 9.75
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics (2004) 8.29
A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol (2008) 6.09
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol (2010) 4.93
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Protein interaction mapping: a Drosophila case study. Genome Res (2005) 4.15
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
LINE-1 activity in facultative heterochromatin formation during X chromosome inactivation. Cell (2010) 3.70
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Mesenchymal stem cell features of Ewing tumors. Cancer Cell (2007) 3.04
Retracted RNAi-dependent and independent control of LINE1 accumulation and mobility in mouse embryonic stem cells. PLoS Genet (2013) 2.91
Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol (2009) 2.88
A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res (2007) 2.88
Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics (2011) 2.86
Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. Bioinformatics (2010) 2.79
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics (2010) 2.63
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med (2010) 2.62
A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet (2012) 2.45
Classification of microarray data using gene networks. BMC Bioinformatics (2007) 2.44
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol (2012) 2.29
miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res (2010) 2.24
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol (2009) 2.15
Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol (2009) 2.04
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet (2004) 1.98
Highly dynamic and sex-specific expression of microRNAs during early ES cell differentiation. PLoS Genet (2009) 1.96
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res (2008) 1.94
VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics (2006) 1.87
Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med (2010) 1.81
Spatial normalization of array-CGH data. BMC Bioinformatics (2006) 1.79
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res (2012) 1.78
MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One (2009) 1.73
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol (2012) 1.71
Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet (2013) 1.69
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer (2008) 1.66
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
BiNoM: a Cytoscape plugin for manipulating and analyzing biological networks. Bioinformatics (2007) 1.65
The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One (2009) 1.63
A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol (2008) 1.61
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res (2009) 1.61
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res (2007) 1.58
Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 1.58
JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell (2007) 1.56
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Germline gain-of-function mutations of ALK disrupt central nervous system development. Hum Mutat (2011) 1.54
Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res (2008) 1.50
A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene (2002) 1.50
Mathematical modelling of cell-fate decision in response to death receptor engagement. PLoS Comput Biol (2010) 1.49
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Principal manifolds and graphs in practice: from molecular biology to dynamical systems. Int J Neural Syst (2010) 1.48
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol (2010) 1.43
Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci U S A (2008) 1.43
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res (2010) 1.42
Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res (2008) 1.39
Genome-wide redistribution of meiotic double-strand breaks in Saccharomyces cerevisiae. Mol Cell Biol (2006) 1.38
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Live-cell chromosome dynamics and outcome of X chromosome pairing events during ES cell differentiation. Cell (2011) 1.36
Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol (2010) 1.36
ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis. Nucleic Acids Res (2006) 1.35
Robust simplifications of multiscale biochemical networks. BMC Syst Biol (2008) 1.30
Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J Pathol (2010) 1.30
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res (2008) 1.30
De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-Seq data analysis. Nucleic Acids Res (2010) 1.30
HiTC: exploration of high-throughput 'C' experiments. Bioinformatics (2012) 1.29
CAPweb: a bioinformatics CGH array Analysis Platform. Nucleic Acids Res (2006) 1.28
SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol (2014) 1.27
Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol (2005) 1.26
Extra-renal non-cerebral rhabdoid tumours. Pediatr Blood Cancer (2008) 1.26
Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J (2010) 1.25